Ethyl 3,4-dihydroxybenzoate

Synonyms: Protocatechuic acid ethyl ester
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) 是一种口服有效、可透过血脑屏障的竞争性脯氨酰羟化酶 (PHD) 抑制剂,通过抑制 PHD 对缺氧诱导因子 (HIF) 的羟基化修饰来稳定 HIF-1α 蛋白,进而激活下游通路诱导肿瘤细胞自噬与凋亡,同时调节炎症反应、抑制 NF-κB 通路、改善血管通透性并促进成骨细胞分化,具有抗肿瘤、抗缺氧损伤及调节骨代谢作用,还可用于心血管保护 (如减轻心肌缺血损伤)、骨组织工程 (促进成骨/抑制破骨分化) 及高原脑水肿防治等领域的研究。
产品编号: MS-C46241 纯度: 99.96% CAS No.: 3943-89-3 分子式: C9H10O4 分子量: 182.18
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) 是一种口服有效、可透过血脑屏障的竞争性脯氨酰羟化酶 (PHD) 抑制剂,通过抑制 PHD 对缺氧诱导因子 (HIF) 的羟基化修饰来稳定 HIF-1α 蛋白,进而激活下游通路诱导肿瘤细胞自噬与凋亡,同时调节炎症反应、抑制 NF-κB 通路、改善血管通透性并促进成骨细胞分化,具有抗肿瘤、抗缺氧损伤及调节骨代谢作用,还可用于心血管保护 (如减轻心肌缺血损伤)、骨组织工程 (促进成骨/抑制破骨分化) 及高原脑水肿防治等领域的研究。

生物实验数据

生物活性 Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits PHD-mediated hydroxylation of hypoxia-inducible factor (HIF), thereby stabilizing HIF-1α protein and activating downstream pathways to induce autophagy and apoptosis in tumor cells while modulating inflammatory responses, inhibiting the NF-κB pathway, improving vascular permeability, and promoting osteoblast differentiation; it exhibits anti-tumor, anti-hypoxic injury, and bone metabolism-regulating effects, and can also be used in research on cardiovascular protection (e.g., alleviating myocardial ischemic injury), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
体外研究
(In Vitro)

1. 食管癌细胞凋亡实验:
Ethyl 3,4-dihydroxybenzoate (50 μg/mL;24-72 h) 在 KYSE 170 和 EC109 食管鳞癌细胞中诱导 S 期细胞周期阻滞、线粒体膜通透性丧失及 caspase 依赖的凋亡,同时上调 NDRG1、BNIP3、Beclin 等蛋白表达。
2.心肌保护实验:
Ethyl 3,4-dihydroxybenzoate (1 mM;15 min,预处理) 可通过 KATP 通道,激活离体心肌细胞的 NOS,增加线粒体的 ROS 水平,发挥心肌保护作用。
3.骨细胞分化实验:
Ethyl 3,4-dihydroxybenzoate (5 mg/mL;7-14 d) 在 MC3T3-E1 成骨前体细胞中显著提升碱性磷酸酶 (ALP) 活性、I 型胶原沉积及矿化结节形成,且在 RAW264.7 破骨细胞中以剂量依赖 (2-4 mg/mL;6 d) 方式抑制 TRAP 阳性多核细胞分化及 TRAP 酶活性。

Apoptosis Analysis

Cell Line: KYSE 170 and EC109 esophageal squamous cell carcinoma cells
Concentration: 50 μg/mL
Incubation Time: 24 h, 36 h, 72 h
Result: Induced S-phase cell cycle arrest, mitochondrial membrane permeabilization, and caspase-dependent apoptosis in KYSE 170 and EC109 cells.
Upregulated autophagy- and apoptosis-related proteins, including NDRG1, BNIP3, and Beclin, with significant reduction in cell viability by 50-70% compared to controls.

Cell Differentiation Assay

Cell Line: MC3T3-E1 preosteoblasts and RAW264.7 monocyte cells
Concentration: 5 mg/mL (MC3T3-E1); 1-4 mg/mL (RAW264.7)
Incubation Time: 3-14 days (MC3T3-E1); 6 days (RAW264.7)
Result: In MC3T3-E1 cells, significantly increased alkaline phosphatase (ALP) activity (2-fold at day 10), collagen type I deposition (1.5-fold at day 14), and mineralized nodule formation (34% increase at week 5).
In RAW264.7 cells, at 2-4 mg/mL dose-dependently reduced TRAP-positive multinucleated osteoclast formation by 54-77% and decreased TRAP enzyme activity, indicating inhibition of osteoclast differentiation.
体内研究
(In Vivo)

1. 骨组织工程体内实验:
Ethyl 3,4-dihydroxybenzoate (5 mg/bead,50 mg/bead;Alginate 凝胶包埋后皮下注射;单次;5-8 周) 在裸鼠皮下移植模型中,促进人源间充质干细胞成骨分化,增加 I 型胶原和骨钙素表达,诱导新生骨组织形成。
2. 高原脑水肿防治实验:
Ethyl 3,4-dihydroxybenzoate (50-100 mg/kg;腹腔注射;每日 1 次;3 天) 在大鼠急性低压缺氧模型中,显著降低脑水含量和血管通透性,下调 TNF-α、IL-6 等促炎因子,上调 HIF-1α、HO-1 等抗氧化蛋白。
3. 心肌缺血保护实验:
Ethyl 3,4-dihydroxybenzoate (75 mg/kg;腹腔注射;每日 1 次;3 天) 在大鼠心肌缺血-再灌注模型中,通过激活 NOS-NO 通路和线粒体 KATP 通道,减少梗死面积,并抑制 NF-κB 介导的炎症反应。

Animal Model: Subcutaneous bone tissue engineering model (Balb/c nude mice) (6 weeks old), subcutaneous transplantation of alginate-encapsulated hMSCs
Dosage: 5 mg/bead or 50 mg/bead, incorporated into alginate gel
Administration: Single subcutaneous injection into the back, observed for 5-8 weeks
Result: Promoted osteogenic differentiation of human mesenchymal stem cells (hMSCs), as shown by von Kossa and Alizarin Red staining for calcium deposition.
Increased expression of collagen type I and osteocalcin in the transplanted tissue, with dose-dependent enhancement (50 mg/bead showing stronger effects).
Resulted organized new bone formation with reduced fibrous tissue compared to control groups.
Animal Model: Myocardial ischemia-reperfusion injury model (Sprague-Dawley rats) (180±20 g), myocardial ischemia-reperfusion injury model
Dosage: 75 mg/kg, dissolved in DMSO/saline
Administration: Intraperitoneal injection, daily for 3 days, followed by 30-min coronary artery occlusion and 120-min reperfusion
Result: Significantly reduced infarct size by 68% compared to controls, associated with increased nitric oxide (NO) production, activation of mitochondrial ATP-sensitive potassium (mitoKATP) channels, and downregulation of nuclear factor-κB (NF-κB)-dependent pro-inflammatory cytokines (TNF-α, IL-6). Western blot analysis showed upregulation of hypoxia-inducible factor-1α (HIF-1α) and heme oxygenase-1 (HO-1), while immunohistochemistry revealed reduced neutrophil infiltration in the ischemic myocardium.
Animal Model: Acute hypobaric hypoxia model (Sprague-Dawley rats) (180±20 g), acute hypobaric hypoxia at 9144 m for 5 h
Dosage: 75 mg/kg, dissolved in DMSO/saline
Administration: Intraperitoneal injection, daily for 3 days prior to hypoxia exposure
Result: Reduced brain water content (edema index) by 10% and vascular permeability (sodium fluorescein leakage) by 49% compared to hypoxic controls.
Decreased levels of pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ) and increased anti-inflammatory IL-10.
Upregulated HIF-1α, HO-1, and metallothionein-1 (MT-1) expression, while NF-κB nuclear translocation and vascular cell adhesion molecule-1 (VCAM-1) expression were significantly attenuated.
性状 固体
颜色 White to off-white

化学信息

分子量 182.18
分子式 C9H10O4
CAS No. 3943-89-3
别名 Protocatechuic acid ethyl ester

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (54.89 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.98 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (548.92 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.4892 mL27.4461 mL54.8923 mL137.2307 mL
5 mM1.0978 mL5.4892 mL10.9785 mL27.4461 mL
10 mM0.5489 mL2.7446 mL5.4892 mL13.7231 mL
15 mM0.3659 mL1.8297 mL3.6595 mL9.1487 mL
20 mM0.2745 mL1.3723 mL2.7446 mL6.8615 mL
25 mM0.2196 mL1.0978 mL2.1957 mL5.4892 mL
30 mM0.1830 mL0.9149 mL1.8297 mL4.5744 mL
40 mM0.1372 mL0.6862 mL1.3723 mL3.4308 mL
50 mM0.1098 mL0.5489 mL1.0978 mL2.7446 mL
60 mM0.0915 mL0.4574 mL0.9149 mL2.2872 mL
80 mM0.0686 mL0.3431 mL0.6862 mL1.7154 mL
100 mM0.0549 mL0.2745 mL0.5489 mL1.3723 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础